A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
Swan LinJason GongGeorge C CanasPeter WinkleKathleen PelletierRobert R LaBadieKatherine GinmanYazdi K PithavalaPublished in: European journal of drug metabolism and pharmacokinetics (2022)
NCT03542305 (available May 31, 2018 on clinicaltrials.gov).
Keyphrases